<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308329">
  <stage>Registered</stage>
  <submitdate>4/08/2009</submitdate>
  <approvaldate>28/08/2009</approvaldate>
  <actrnumber>ACTRN12609000748213</actrnumber>
  <trial_identification>
    <studytitle>A targeted community program of vitamin D treatment to reduce hospital admissions for falls, fractures and other disorders</studytitle>
    <scientifictitle>A randomised controlled placebo-controlled study to evaluate the effects of vitamin D treatment on reducing hospital admissions for falls, fractures and other disorders in elderly women</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Falls in the elderly</healthcondition>
    <healthcondition>Fractures in the elderly</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>150,000 IU vitamin D (cholecalciferol) taken orally as 3 capsules at three clinic visits three months apart; lifestyle advice on physical activity and calcium intake given at baseline through an information sheet administered by trained research assistants</interventions>
    <comparator>Three identical placebo capsules made of lactose taken orally at three clinic visits three months apart; lifestyle advice on physical activity and calcium intake given at baseline through an information sheet administered by trained research assistants</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Lifestyle</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Falls events in general as recorded by subjects on a condition and medication logbook and reviewed at clinic visits three months apart by trained research assistants</outcome>
      <timepoint>At 9 months after intervention commencement</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Falls events (as recorded by subjects on a condition and medication logbook and reviewed at clinic visits three months apart by trained research assistants) in winter/spring</outcome>
      <timepoint>At 9 months after intervention commencement</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Falls events (as recorded by subjects on a condition and medication logbook and reviewed at clinic visits three months apart by trained research assistants) in those with baseline serum 25-hydroxyvitamin D (25(OH)D) levels less than 60 nmol/L.</outcome>
      <timepoint>At 9 months after intervention commencement</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serum 25-hydroxyvitamin D (25OHD) levels as assessed by the Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) method</outcome>
      <timepoint>At 3, 6 and 9 months after intervention commencement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events including vascular diseases, cancer, hypocalcaemia and renal calculus as recorded by subjects on a condition and medication logbook and reviewed at clinic visits three months apart by trained research assistants</outcome>
      <timepoint>At 9 months after intervention commencement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Direct costs of the intervention and the costs of falls related adverse events</outcome>
      <timepoint>At 9 months after intervention commencement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mobility function as assessed by the Timed Up and Go test and hand grip strength as assessed by a hand dynamometer</outcome>
      <timepoint>At 3, 6 and 9 months after intervention commencement</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Females age over 70;
2. a) Registered with a General Practitioner (GP) attached to the practices selected for the study or
b) Registered with a General Practitioner  and able to contact her General Practitioner in Perth;
3. Likely to be able to attend their General Practitioner practice or Sir Charles Gairdner Hospital for four study visits over nine months.</inclusivecriteria>
    <inclusiveminage>70</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Consuming a vitamin D supplement either in isolation or as part of a combination treatment of greater than 200 IU per day, eg. Actonel combi +D or Fosamax plus; 
2. A mini mental state score of less than 24;
3. Individuals who in the investigators opinion would not be suitable for the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subjects numbers were allocated by the pharmacy who has no contact with study participants</concealment>
    <sequence>Computer-generated randomisation sequence</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/02/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>660</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor RL Prince</primarysponsorname>
    <primarysponsoraddress>Bone and Calcium Research Group, School of Medicine and Pharmacology, University of Western Australia, Department of Endocrinology and Diabetes, 1st Floor C Block, Sir Charles Gairdner Hospital, Hospital Ave, Nedlands WA 6009</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Western Australia Department of Health</fundingname>
      <fundingaddress>189 Royal St, East Perth, WA 6004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Western Australia</sponsorname>
      <sponsoraddress>Stirling Highway, Crawley, WA 6009</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Sir Charles Gairdner Hospital</sponsorname>
      <sponsoraddress>Hospital Ave, Nedlands, WA 6009</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a nine-month randomised controlled study to evaluate the effects of vitamin D 150,000 IU per three months on risk of falling, serum vitamin D levels, mobility function and muscle strength in women aged 70 years and over at a community setting.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>1st Floor E Block, Sir Charles Gairdner Hospital, Hospital Ave, Nedlands, WA 6009</ethicaddress>
      <ethicapprovaldate>9/10/2008</ethicapprovaldate>
      <hrec>2008-103</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Richard L Prince</name>
      <address>Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA 6009</address>
      <phone>+61 8 9346 3488</phone>
      <fax>+61 8 9346 1317</fax>
      <email>richard.prince@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Richard L Prince</name>
      <address>Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA 6009</address>
      <phone>+61 8 9346 3488</phone>
      <fax>+61 8 9346 1317</fax>
      <email>richard.prince@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Kun Zhu</name>
      <address>Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA 6009</address>
      <phone>+61 8 9346 4969</phone>
      <fax>+61 8 9346 4109</fax>
      <email>kathyz@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>